Infección por el VIH y farmacocinética de antivirales

An evidence-based bundle improves the quality of care and outcomes of patients with candidaemia

Antifungal treatment administered in OPAT programs is a safe and effective option in selected patients

CD300a identifies a CD4(+)memory T cell subset with a higher susceptibility to HIV-1 infection

Ceftriaxone pharmacokinetics by a sensitive and simple LC-MS/MS method: Development and application

Characteristics and Outcomes of Staphylococcus aureus Bloodstream Infection Originating From the Urinary Tract: A Multicenter Cohort Study

Clinical and prognostic differences between methicillin-resistant and methicillin-susceptible Staphylococcus aureus infective endocarditis

Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study

Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study

Enterococcus faecalis Endocarditis and Outpatient Treatment: A Systematic Review of Current Alternatives

Factors associated with the development of septic shock in patients with candidemia: a post hoc analysis from two prospective cohorts

Genetic diversity of HIV in seminal plasma remains higher than in blood after short-term antiretroviral therapy

Health Care-Associated Infection in Solid Organ Transplant Recipients

Immunological history governs human stem cell memory CD4 heterogeneity via the Wnt signaling pathway

Is immune recovery different depending on the use of integrase strand transfer inhibitor-, non-nucleoside reverse transcriptase- or boosted protease inhibitor-based regimens in antiretroviral-naive HIV-infected patients?

Lack of impact of protease inhibitor resistance-associated mutations on the outcome of HIV-1-infected patients switching to darunavir-based dual therapy

Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients

Mesenchymal stromal cells in Human Immunodeficiency Virus-infected patients with discordant immune response: Early results of a phase I/II clinical trial

Modulation of Monocyte Activation and Function during Direct Antiviral Agent Treatment in Patients Coinfected with HIV and Hepatitis C Virus

Optimization of piperazine-derived ureas privileged structures for effective antiadenovirus agents

PLA2G1B is involved in CD4 anergy and CD4 lymphopenia in HIV-infected patients

Permanent control of HIV-1 pathogenesis in exceptional elite controllers: a model of spontaneous cure

Persistent HIV-controllers are more prone to spontaneously clear HCV: a retrospective cohort study

Polyfunctional HIV-1 specific response by CD8+T lymphocytes expressing high levels of CD300a

Sequential antimicrobial therapy in mediastinitis after cardiac surgery: An observational study of 81 cases

The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations

Therapy of Staphylococcus aureus bacteremia: Evidences and challenges

BRIEF REPORT: RESPONSE TO HEPATITIS A VIRUS VACCINE IN HIV-INFECTED PATIENTS WITHIN A RETROSPECTIVE, MULTICENTRIC COHORT: FACING HEPATITIS A OUTBREAKS IN THE CLINICAL PRACTICE.

CHOICE OF THE INITIAL ANTIRETROVIRAL TREATMENT FOR HIV-POSITIVE INDIVIDUALS IN THE ERA OF INTEGRASE INHIBITORS.

DOLAMA STUDY: EFFECTIVENESS, SAFETY AND PHARMACOECONOMIC ANALYSIS OF DUAL THERAPY WITH DOLUTEGRAVIR AND LAMIVUDINE IN VIROLOGICALLY SUPPRESSED HIV-1 PATIENTS.

EXECUTIVE SUMMARY OF THE GESIDA CONSENSUS DOCUMENT ON CONTROL AND MONITORING OF HIV-INFECTED PATIENTS.

EXECUTIVE SUMMARY OF THE GESIDA/NATIONAL AIDS PLAN CONSENSUS DOCUMENT ON ANTIRETROVIRAL THERAPY IN ADULTS INFECTED BY THE HUMAN IMMUNODEFICIENCY VIRUS (UPDATED JANUARY 2018).

GENTAMICIN AS EMPIRICAL TREATMENT IN HEMODIALYSIS PATIENTS: SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS.

HEPATITIS C VIRUS AND CUMULATIVE INFECTIONS ARE ASSOCIATED WITH ATHEROGENIC CARDIOVASCULAR EVENTS IN HIV-INFECTED SUBJECTS.

HEPATITIS C VIRUS GENOTYPE 1 INFECTION: PREVALENCE OF NS5A AND NS5B RESISTANCE-ASSOCIATED SUBSTITUTIONS IN NAÏVE PATIENTS FROM ARGENTINA.

HIGH CD8 T CELL PERCENTAGE AND HCV REPLICATION CONTROL ARE COMMON FEATURES IN HIV-1 CONTROLLERS AND HTLV-2-CO-INFECTED PATIENTS WITH A HISTORY OF INJECTION DRUG USE.

HIGH EFFICACY OF RESISTANCE-GUIDED RETREATMENT OF HCV PATIENTS FAILING NS5A INHIBITORS IN THE REAL WORLD.

HIGH-RESOLUTION ANOSCOPY IN HIV-INFECTED MEN: ASSESSMENT OF THE LEARNING CURVE AND FACTORS THAT IMPROVE THE PERFORMANCE.

HIGH-RISK HUMAN PAPILLOMA VIRUS TESTING IMPROVES DIAGNOSTIC PERFORMANCE TO PREDICT MODERATE- TO HIGH-GRADE ANAL INTRAEPITHELIAL NEOPLASIA IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED MEN WHO HAVE SEX WITH MEN IN LOW-TO-ABSENT CYTOLOGICAL ABNORMALITIES.

IL-7/IL-7R GENE VARIANTS IMPACT CIRCULATING IL-7/IL-7R HOMEOSTASIS AND ART-ASSOCIATED IMMUNE RECOVERY STATUS.

IL7RA RS6897932 POLYMORPHISM IS ASSOCIATED WITH BETTER CD4+ T-CELL RECOVERY IN HIV INFECTED PATIENTS STARTING COMBINATION ANTIRETROVIRAL THERAPY.

IMMUNOMETABOLISM IS A KEY FACTOR FOR THE PERSISTENT SPONTANEOUS ELITE CONTROL OF HIV-1 INFECTION.

INCIDENCE OF LYMPHOMA IN HIV-HCV-INFECTED PATIENTS. MODIFICATIONS IN FUNCTION OF THE ANTI-HEPATITIS C VIRUS THERAPY.

LOWER EXPRESSION OF PLASMA-DERIVED EXOSOME MIR-21 LEVELS IN HIV-1 ELITE CONTROLLERS WITH DECREASING CD4 T CELL COUNT.

NOVEL ASSOCIATION OF FIVE HLA ALLELES WITH HIV-1 PROGRESSION IN SPANISH LONG-TERM NON PROGRESSOR PATIENTS.

PARENTERAL DRUG USE AS THE MAIN BARRIER TO HEPATITIS C TREATMENT UPTAKE IN HIV-INFECTED PATIENTS.

PROTEOMIC PROFILE ASSOCIATED WITH LOSS OF SPONTANEOUS HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 ELITE CONTROL.

REAL-WORLD EVIDENCE OF THE EFFECTIVENESS OF OMBITASVIR-PARITAPREVIR/R ± DASABUVIR ± RIBAVIRIN IN PATIENTS MONOINFECTED WITH CHRONIC HEPATITIS C OR COINFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS-1 IN SPAIN.

REASONS FOR NONCOMPLIANCE WITH THE NATIONAL GUIDELINES FOR INITIAL ANTIRETROVIRAL THERAPY OF HIV-INFECTED PATIENTS IN SPAIN, 2010-2015.

REPOSITIONING SALICYLANILIDE ANTHELMINTIC DRUGS TO TREAT ADENOVIRUS INFECTIONS.

RESPONSE TO A REINFORCED HEPATITIS B VACCINATION SCHEME IN HIV-INFECTED PATIENTS UNDER REAL-LIFE CONDITIONS.

RISK OF HIV TRANSMISSION THROUGH CONDOMLESS SEX IN SERODIFFERENT GAY COUPLES WITH THE HIV-POSITIVE PARTNER TAKING SUPPRESSIVE ANTIRETROVIRAL THERAPY (PARTNER): FINAL RESULTS OF A MULTICENTRE, PROSPECTIVE, OBSERVATIONAL STUDY.

SPATIOTEMPORAL CHARACTERISTICS OF THE LARGEST HIV-1 CRF02_AG OUTBREAK IN SPAIN: EVIDENCE FOR ONWARD TRANSMISSIONS.

SURVEILLANCE OF TRANSMITTED DRUG RESISTANCE TO INTEGRASE INHIBITORS IN SPAIN: IMPLICATIONS FOR CLINICAL PRACTICE.

T CELLS REQUIRES ALPHA-1 ANTITRYPSIN AS OBSERVED BY TREATMENT IN HIV-1 INFECTED AND UNINFECTED CONTROLS.

VDR RS2228570 POLYMORPHISM IS RELATED TO NON-PROGRESSION TO AIDS IN ANTIRETROVIRAL THERAPY NAÏVE HIV-INFECTED PATIENTS.

Absolute CD4+ T cell count overstate immune recovery assessed by CD4+/CD8+ ratio in HIV-infected patients on treatment.

Altered Expression of CD300a Inhibitory Receptor on CD4+ T Cells From Human Immunodeficiency Virus-1-Infected Patients: Association With Disease Progression Markers.

Association of heterozygous CCR5Δ32 deletion with survival in HIV-infection: A cohort study.

Circulating metabolomic profile can predict dyslipidemia in HIV patients undergoing antiretroviral therapy.

Class-modeling analysis reveals T-cell homeostasis disturbances involved in loss of immune control in elite controllers.

Consensus document on the diagnosis and treatment of sexually transmitted diseases in adults, children and adolescents.

Control of HIV-1 Pathogenesis in Viremic Nonprogressors Is Independent of Gag-Specific Cytotoxic T Lymphocyte Responses.

Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations.

Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients.

Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection.

Immune Correlates of Natural HIV Elite Control and Simultaneous HCV Clearance-Supercontrollers.

Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort.

Improved CD4 T cell profile in HIV-infected subjects on maraviroc-containing therapy is associated with better responsiveness to HBV vaccination.

Increased frequencies of Th17 cells and IL17a-producing regulatory T-cells preceding the immunodiscordant response to antiretroviral treatment.

Long-term Persistent Elite HIV-controllers: The Right Model of Functional Cure.

Losses to follow-up of HIV-infected people in the Spanish VACH cohort over the period between 2013 and 2014: The importance of sociodemographic factors.

No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients.

Pegylated Interferon-α-Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapy-Treated HIV-1/Hepatitis C Virus-Coinfected Patients.

Prevalence of hepatitis C virus infection according to the year of birth: identification of risk groups.

Role of APOBEC3H in the Viral Control of HIV Elite Controller Patients.

Role of toll-like receptor 4 Asp299Gly polymorphism in the development of cardiovascular diseases in HIV-infected patients.

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus

Toll-Like Receptor 7 (TLR-7) and TLR-9 Agonists Improve Hepatitis C Virus Replication and Infectivity Inhibition by Plasmacytoid Dendritic Cells.

A Lower Baseline CD4/CD8 T-Cell Ratio Is Independently Associated with Immunodiscordant Response to Antiretroviral Therapy in HIV-Infected Subjects.

Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response.

CCR5+ CD8 T-cell levels and monocyte activation precede the onset of acute coronary syndrome in HIV-infected patients on antiretroviral therapy.

Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection. (1)

Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies.

HIV-1 p24 and CD4(+)T cell count during boosted protease-inhibitor monotherapy in HIV-infected patients.

HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study.

HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers

Higher levels of IL-6, CD4 turnover and Treg frequency are already present before cART in HIV-infected subjects with later low CD4 recovery.

Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers.

Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy.

Increased CD127+ and decreased CD57+ T cell expression levels in HIV-infected patients on NRTI-sparing regimens

Pharmacokinetic interactions between cobicistat-boosted elvitegravir and darunavir in HIV-infected patients.

Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach.

Relationship between CCR5(WT/Δ32) heterozygosity and HIV-1 reservoir size in adolescents and young adults with perinatally acquired HIV-1 infection

Rilpivirine: The Key for Long-term Success.

Thymic Function Failure Is Associated With Human Immunodeficiency Virus Disease Progression.

Thymic Function Impacts the Peripheral CD4/CD8 Ratio of HIV-Infected Subjects.

Very low level viraemia and risk of virological failure in treated HIV-1-infected patients.

Viral Kinetics in Semen With Different Antiretroviral Families in Treatment-Naive Human Immunodeficiency Virus-Infected Patients: A Randomized Trial.